Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Matthew Dillon

Physician Assistant, Medical Jonesville, MI Physician Assistant

NPI 1508099649 CMS profile 10747857

216 Olds St, Jonesville, MI 49250

Open in the dashboard

General payments

$9,437

573 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Dillon of Jonesville, MI is reported in the CMS Open Payments database as having received $9,437 across 573 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,574 79
2024 General $1,641 92
2023 General $2,401 140
2022 General $1,723 114
2021 General $2,098 148

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Dillon
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Matthew Dillon were reported at $1,574. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Matthew Dillon Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,098 $156 $41–$563 $132
2022 $1,723 $185 $55–$649 $149
2023 $2,401 $199 $58–$717 $160
2024 $1,641 $206 $62–$740 $164
2025 $1,574 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,411 89 payments
  2. Lilly USA, LLC $878 51 payments
  3. AbbVie, Inc. $758 53 payments
  4. Otsuka America Pharmaceutical, Inc. $660 44 payments
  5. Pfizer Inc. $651 37 payments
  6. AstraZeneca Pharmaceuticals LP $623 29 payments
  7. GlaxoSmithKline, LLC. $478 46 payments
  8. Actelion Pharmaceuticals US, Inc. $453 15 payments
  9. Merck Sharp & Dohme Corporation $446 24 payments
  10. Janssen Pharmaceuticals, Inc $343 33 payments
  11. Other $2,736 152 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,239 571 payments
  2. Education $198 2 payments
Products named General payments · program years 2021–2025
  1. Ozempic $678 41 payments
  2. REXULTI $660 44 payments
  3. Wegovy $506 28 payments
  4. MOUNJARO $492 25 payments
  5. NURTEC ODT $472 28 payments
  6. OPSUMIT $453 15 payments
  7. TRELEGY ELLIPTA $434 43 payments
  8. UPTRAVI $432 14 payments
  9. VRAYLAR $414 31 payments
  10. RYBELSUS $407 24 payments
  11. Other $8,598 508 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 87 drugs

Part D claims

3,631

Median for Physician Assistant: 241

Drug cost

$282,058

Median for Physician Assistant: $4,110

Branded share of claims

20.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 42 $38,131
Mounjaro Tirzepatide Brand 35 $36,937
Vraylar Cariprazine Hcl Brand 15 $35,602
Jardiance Empagliflozin Brand 21 $30,246
Xarelto Rivaroxaban Brand 35 $28,042
Eliquis Apixaban Brand 30 $27,804
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 29 $26,314
Ozempic Semaglutide Brand 13 $12,385
Albuterol Sulfate Hfa Albuterol Sulfate Brand 125 $4,348
Breo Ellipta Fluticasone/Vilanterol Brand 11 $4,261

The 10 drugs with the highest cost, of 87 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $157
  • Lundbeck LLC $138
$295 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $133
$133 29 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $101
$101 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $101
$101 — —
Wegovy
  • Novo Nordisk Inc $98
$98 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

573 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record